Keyword: Versant Ventures
Last year, we asked: Are too many early-stage biotechs going for IPOs, and when will the bubble burst?
Coda Therapeutics is adding another $15 million to the bank and detailing its first two programs: chronic neuropathic pain and focal epilepsy.
Vensana Capital has launched with a $225 million fund and ambitions to support new breakthroughs in medical devices, diagnostics and data science.
Repare Therapeutics plans to start testing ATR inhibitor RP-3500 in the clinic next year while putting a second asset through preclinical studies.
Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.
The deal will give Bayer control of an induced pluripotent stem cell pipeline led by a late-preclinical Parkinson’s disease candidate.
Versant Ventures’ Century Therapeutics has exited stealth with $250 million to take anticancer allogeneic cell therapies into the clinic.
Nuvaira has raised $79 million in equity financing to continue late-stage clinical development of its device-based treatment for COPD in the U.S.
The series B tees the allosteric oncogenic mutation specialist up to move two or three candidates into the clinic.
Versant Ventures unveiled a $600 million global biotech fund, its seventh, and a $100 million companion fund that will focus on startups in Canada.